New cellular model for rare and deadly melanomas enables study of immunotherapy resistance
A research team at the University of Turku in Finland has developed a reliable laboratory model to study BAP1-deficient melanomas, which are a rare type of melanoma that evade the immune system once they have metastasized and are universally resistant to current state-of-the-art immunotherapies. The tool could change how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.
The health section covers stories about medical progress, recovery, and wellbeing. We look for genuine advances: new therapies clearing regulatory hurdles, diseases being eradicated in specific regions, communities improving public health outcomes through evidence-based programs. Celebrity wellness trends and supplement marketing do not make the cut.
Dr Bill Kirkup says he resigned from a government-commissioned review into NHS maternity services over the omission.
A common brain protein may be giving Alzheimer’s disease an unexpected way to spread, carrying toxic Tau proteins from d…
Personal finance and nutrition experts share simple strategies that make it possible to eat out without spending a fortu…
Aid for brain-bleed recovery receives FDA Breakthrough Device Designation WashU Medicine